Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01263847 · ClinicalTrials.gov registry record · Early Phase 1

Galactooligosaccharide (GOS) Supplementation and Calcium Absorption in Girls

A Early Phase 1 study, sponsored by Purdue University.

Completed
Registry status
Early Phase 1
Development phase
31
Enrollment target

NCT01263847 is a Early Phase 1 study that has completed, run by Purdue University. The registered enrollment target is 31 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01263847, a Early Phase 1 study, has completed, sponsored by Purdue University.

COMPLETED
Registry status
Early Phase 1
Development phase
31 participants
Enrollment target

Study Summary

The purpose of this study is to determine the effects of galactooligosaccharide (GOS) supplementation on calcium absorption and and gut microbe profiles.

Interventions

  • DIETARY_SUPPLEMENT Galactooligosaccharide

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2009-06
Est. Completion 2010-07
Phase Early Phase 1

Sponsor

Purdue University

141 total trials

What the Registry Record Tells You About NCT01263847

The ClinicalTrials.gov registry entry for NCT01263847 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Purdue University, which has 141 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Galactooligosaccharide is the first listed.

NCT01263847 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01263847 about?

NCT01263847 is a clinical study titled "Galactooligosaccharide (GOS) Supplementation and Calcium Absorption in Girls". The purpose of this study is to determine the effects of galactooligosaccharide (GOS) supplementation on calcium absorption and and gut microbe profiles.

What is the current status of trial NCT01263847?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 31 participants. The study started on 2009-06. Estimated completion is 2010-07.

What interventions are being tested in trial NCT01263847?

The interventions under investigation include: Galactooligosaccharide (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01263847?

This trial is sponsored by Purdue University, which has 141 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.